Luxsol™ - 3V Medical Research Group

About Luxsol™

Luxsol™ is one of the few treatments in the USA to be covered by a patent granted by the USPTO to treat Covid-19 virus and Influenza:

US Patent No. 11,000,545 on May 11, 2021

Luxsol™

What is Luxsol™? Luxsol™ is a suspension that is intended for use as a targeted treatment for respiratory illness associated with Covid-19 and influenza. It is not a pill or an injection. It is a spray through the mouth delivering drug directly to lungs using a nebulizer.

Side Effects

Side effects are unknown at this stage, as the drug has not entered human studies. However, based on human experience with Luxsol™ side effects are expected to be both rare and mild.

History of Luxsol™

Luxsol™ was successfully tested in the treatment of Covid-19 in an In vitro study using Remdesivir as the positive control. Both drugs were equally effective killing the SARS-COV-2 virus.

Luxsol™ is one of the few treatments in the USA to be covered by a USPTO patent to treat Covid-19 virus and Influenza.

3V Medical Research Group developed Luxsol™ as a targeted therapeutic.

archive